Effects of SEMOTIADIL (cas 116476-13-2) fumarate (SD-3211) on renal hemodynamics and function in dogs
-
Add time:08/15/2019 Source:sciencedirect.com
Studies were carried out to define the effect of SEMOTIADIL (cas 116476-13-2) on renal hemodynamics, renal function and renin release in pentobarbital-anesthetized dogs. Intrarenal arterial infusion of semotiadil resulted in a significant increase in renal blood flow (RBF), glomerular filtration rate (GFR), urine flow, urinary excretion of electrolytes and renin release. Semotiadil did not affect the linear relationship between osmolar clearance and the free water reabsorption rate, and increased the urinary excretion of sodium and calcium to the same extent. These results suggest that the main tubular site of action of semotiadil is the proximal tubule. Intrarenal infusion of a potent non-peptide angiotensin II antagonist, DuP753 (15 μg/kg per min), resulted in an increase in RBF, GFR, urine flow and UNaV. In spite of the blockade of the intrarenal renin angiotensin system(RAS) with DuP753, semotiadil caused almost the same effects as it did in the absence of DuP753. These results suggest that the renal effects of semotiadil are independent of the intrarenal RAS.
We also recommend Trading Suppliers and Manufacturers of SEMOTIADIL (cas 116476-13-2). Pls Click Website Link as below: cas 116476-13-2 suppliers
Prev:SEMOTIADIL (cas 116476-13-2) improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem
Next:Regular paperEffects of SEMOTIADIL (cas 116476-13-2), a novel Ca2+ channel antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipine) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Regular ArticleSEMOTIADIL (cas 116476-13-2), a new calcium antagonist, is a very potent inhibitor of LDL-oxidation08/22/2019
- Synthesis of azido derivatives of SEMOTIADIL (cas 116476-13-2), a novel 1,4-benzothiazine calcium antagonist, for photoaffinity probes of calcium channels08/21/2019
- Synthesis and in vivo evaluation of [11C]SEMOTIADIL (cas 116476-13-2), a benzothiazine calcium antagonist08/20/2019
- Enantioselective protein binding of SEMOTIADIL (cas 116476-13-2) and levoSEMOTIADIL (cas 116476-13-2) determined by high-performance frontal analysis☆08/19/2019
- A novel benzothiazine Ca2+ channel antagonist, SEMOTIADIL (cas 116476-13-2), inhibits cardiac L-type Ca2+ currents08/18/2019
- Photochemical localization of the SEMOTIADIL (cas 116476-13-2) binding region within the cardiac Ca2+ channel α1 subunit. Comparison with the skeletal muscle counterpart08/17/2019
- Regular paperEffects of SEMOTIADIL (cas 116476-13-2), a novel Ca2+ channel antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipine08/16/2019
- SEMOTIADIL (cas 116476-13-2) improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem08/14/2019
- Regular ArticleAntiplatelet activity of SEMOTIADIL (cas 116476-13-2) fumarate08/13/2019


